VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Voyager Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.05+0.15 (+7.89%)
Close on Oct 19, 2026
- Market cap
- $124.12M
- P/E (TTM)
- –
- Dividend yield
- –
Voyager Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Voyager Therapeutics | Industry median |
|---|---|---|
| Market Cap | $126.32M | $164.85M |
| Enterprise Value | -$22.48M | $87.06M |
| PS Ratio | 3.67 | 3.60 |
| PB Ratio | 0.82 | 2.03 |
| P/TBV Ratio | 0.82 | 2.31 |
Enterprise value
| Measure | Voyager Therapeutics | Industry median |
|---|---|---|
| EV / Sales | -0.65 | 2.43 |
Income (trailing twelve months)
| Measure | Voyager Therapeutics | Industry median |
|---|---|---|
| Revenue | $34.46M | $57.94M |
| Operating Income | -$117.19M | -$21.44M |
| Pretax Income | -$107.60M | -$14.45M |
| Net Income | -$107.73M | -$22.46M |
| EBITDA | -$117.19M | -$16.91M |
| EPS (Diluted) | -$1.81 | -$0.83 |
Margins
| Measure | Voyager Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -340.1% | -44.5% |
| Pretax Margin | -312.3% | -13.0% |
| Profit Margin | -312.6% | -39.2% |
| EBITDA Margin | -340.1% | -31.3% |
| FCF Margin | -352.4% | -8.85% |
Returns
| Measure | Voyager Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -54.1% | -53.1% |
| Return on Assets (ROA) | -41.4% | -41.0% |
| Return on Capital Employed (ROCE) | -64.7% | -37.8% |
Growth
| Measure | Voyager Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -19.1% | 6.01% |
| Revenue Growth (3Y CAGR) | -0.44% | 2.25% |
| Revenue Growth (5Y CAGR) | -25.1% | 6.42% |
Balance sheet
| Measure | Voyager Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $148.80M | $62.42M |
| Net Cash (Debt) | $148.80M | $15.68M |
| Net Cash Per Share | $2.41 | $0.66 |
| Equity (Book Value) | $154.38M | $48.79M |
| Book Value Per Share | $2.51 | $1.36 |
| Tangible Book Value | $154.38M | $23.06M |
| Working Capital | $108.54M | $75.77M |
Financial position
| Measure | Voyager Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 7.51 | 3.30 |
| Quick Ratio | 9.09 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Voyager Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$120.57M | -$12.35M |
| Capital Expenditures | -$847.00K | -$1.06M |
| Free Cash Flow | -$121.42M | -$20.28M |
| FCF Per Share | -$1.97 | -$0.42 |
Efficiency
| Measure | Voyager Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.13 | 0.38 |
| Revenue Per Employee | $244.39K | $398.96K |
| Profits Per Employee | -$764.03K | -$703.34K |
| Employee Count | 141 | 74 |
Dividends and yields
| Measure | Voyager Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -85.3% | -22.7% |
| FCF Yield | -96.1% | -9.07% |
Shares
| Measure | Voyager Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 61,617,900 | 58,179,650 |
| Shares Change (YoY) | 2.12% | 11.1% |
| Shares Change (QoQ) | 1.60% | 0.54% |
| Float | 60,122,100 | 49,173,100 |
| Shares Held by Insiders | 2.43% | 11.6% |
| Shares Held by Institutions | 56.9% | 59.4% |
Taxes
| Measure | Voyager Therapeutics | Industry median |
|---|---|---|
| Income Tax | $126.00K | $91.50K |
Scores
| Measure | Voyager Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -2.90 | -0.24 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Voyager Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.